Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

VRDN

Viridian Therapeutics Inc

Sep 20 • 03:19PM ET

22.17

Dollar change -0.33
Percentage change -1.47	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM XBI VTI VXF IWO SCHA VTWO IWN IWC LABU

Index	RUT	P/E	-	EPS (ttm)	-4.25	Insider Own	13.04%	Shs Outstand	74.56M	Perf Week	0.50%
Market Cap	1.65B	Forward P/E	-	EPS next Y	-4.18	Insider Trans	19.70%	Shs Float	64.83M	Perf Month	42.30%
Income	-228.06M	PEG	-	EPS next Q	-1.06	Inst Own	84.43%	Short Float	12.39%	Perf Quarter	76.37%
Sales	0.29M	P/S	5699.98	EPS this Y	27.08%	Inst Trans	15.43%	Short Ratio	5.40	Perf Half Y	18.05%
Book/sh	6.00	P/B	3.69	EPS next Y	-7.99%	ROA	-48.67%	Short Interest	8.03M	Perf Year	35.43%
Cash/sh	7.66	P/C	2.89	EPS next 5Y	-	ROE	-53.97%	52W Range	10.93 - 24.18	Perf YTD	1.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.35%	ROI	-37.77%	52W High	-8.31%	Beta	1.07
Dividend TTM	-	Quick Ratio	23.99	Sales past 5Y	-12.71%	Gross Margin	-407.64%	52W Low	102.93%	ATR (14)	1.56
Dividend Ex-Date	-	Current Ratio	23.99	EPS Y/Y TTM	12.78%	Oper. Margin	-87078.82%	RSI (14)	73.00	Volatility	8.23% 8.48%
Employees	96	Debt/Eq	0.04	Sales Y/Y TTM	-80.41%	Profit Margin	-79185.76%	Recom	1.12	Target Price	38.44
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	20.05%	Payout	-	Rel Volume	0.80	Prev Close	22.50
Sales Surprise	-7.93%	EPS Surprise	-17.15%	Sales Q/Q	0.00%	Earnings	Aug 08 BMO	Avg Volume	1.49M	Price	22.17
SMA20	28.98%	SMA50	37.82%	SMA200	33.38%	Trades		Volume	1,077,528	Change	-1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51
Dec-01-22	Initiated	H.C. Wainwright	Buy	$35
Jun-23-22	Initiated	B. Riley Securities	Buy	$25
Nov-18-21	Initiated	SVB Leerink	Outperform	$32
Oct-12-21	Initiated	Evercore ISI	Outperform	$40
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$40

Show Previous Ratings

Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
08:15AM	Loading…
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
04:01PM	Loading…
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%
Apr-29-24 08:00AM	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 (Business Wire) +5.59%
Apr-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Feb-28-24 09:55AM	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% (Zacks)
Feb-27-24 04:01PM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:00AM	Loading…
Feb-16-24 08:00AM	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer (Business Wire)
Feb-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-17-24 10:00PM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock (Business Wire) -9.73%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire)
Jan-08-24 08:00AM	Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference (Business Wire) +7.78%
Jan-04-24 08:00AM	Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 07:00AM	Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease (Business Wire) +9.52%
Nov-21-23 08:00AM	Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 05:00PM	Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +8.79%
04:01PM	Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-23 08:00AM	Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:00AM	Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology (Business Wire) +7.88%
Oct-30-23 08:30AM	Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing (Business Wire) +5.17%
Oct-26-23 08:00AM	Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease (Business Wire) +8.57%
Sep-25-23 08:00AM	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors (Business Wire)
Sep-07-23 08:00AM	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September (Business Wire)
Aug-08-23 04:01PM	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +5.69%
Aug-04-23 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-10-23 04:01PM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-23 08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society (Business Wire)
Jun-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 04:01PM	Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections (GlobeNewswire)
May-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 (GlobeNewswire)
Apr-20-23 01:41PM	UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-13-23 06:52AM	Daily Vickers Top Buyers & Sellers for 04/13/2023 (Argus Research)
Apr-12-23 08:00AM	Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer (GlobeNewswire)
Apr-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-23 07:00AM	Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) -10.48%
Mar-07-23 08:00AM	Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (GlobeNewswire)
Mar-03-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 08:00AM	Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-28-23 08:00AM	Viridian Therapeutics to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 08:00AM	Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire)
Feb-06-23 07:00AM	Viridian Appoints Scott Myers as President and Chief Executive Officer (GlobeNewswire)
Feb-02-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-23 08:00AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Jan-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 08:00AM	Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 07:00AM	Viridian Therapeutics Announces First Patient Enrolled in the THRIVE Phase 3 Trial in Patients With Thyroid Eye Disease (GlobeNewswire) +7.34%
Dec-07-22 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 07:00AM	Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-16-22 05:10AM	Viridian Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 07:01AM	Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:59AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Nov-08-22 07:05AM	Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th (GlobeNewswire)
07:00AM	Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022 (GlobeNewswire)
Oct-22-22 02:04PM	Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting (GlobeNewswire)
Oct-12-22 08:12AM	Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting (GlobeNewswire)
Sep-02-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-31-22 08:00AM	Why Viridian's CEO Isn't Sweating His Company's Second-Place Position (Investor's Business Daily)
Aug-25-22 04:03PM	Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-17-22 08:59AM	Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet? (Simply Wall St.) -10.67%
06:00AM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (GlobeNewswire)
Aug-15-22 04:35PM	New Contender Viridian Takes Aim At Horizon's Eye Drug, And Rockets (Investor's Business Daily) +49.36% +15.91%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (GlobeNewswire)
02:17PM	Options Traders Blast Surging Biotech Stock After Earnings (Schaeffer's Investment Research)
07:02AM	Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:59AM	Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Aug-08-22 08:00AM	Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022 (GlobeNewswire)
Aug-05-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 07:00AM	Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer (GlobeNewswire) +6.36%
Jun-03-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.69%
Jun-01-22 08:00AM	Viridian Therapeutics to Participate in June Investor Conferences (GlobeNewswire)
May-12-22 04:05PM	Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) +5.49% +28.03%

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Sep 13 '24	Buy	18.75	1,600,000	30,000,000	3,445,813	Sep 17 09:00 PM
Fairmount Funds Management LLC	Director	Jan 22 '24	Buy	21.00	476,190	9,999,990	1,839,954	Jan 24 06:44 PM

Open in Screener

ZBIO

Zenas Biopharma Inc.

Sep 20 • 03:16PM ET

18.45

Dollar change +0.93
Percentage change 5.30	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Financials • Options • Save to Portfolio • Create Alert

ZBIO Zenas Biopharma Inc. daily Stock Chart

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	38.32M	Perf Week	1.64%
Market Cap	734.05M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	21.49M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	10.05%	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-7.54	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	4.62	P/C	3.99	EPS next 5Y	-	ROE	-	52W Range	17.02 - 18.99	Perf YTD	1.64%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-2.85%	Beta	-
Dividend TTM	-	Quick Ratio	4.82	Sales past 5Y	-	Gross Margin	-	52W Low	8.39%	ATR (14)	0.97
Dividend Ex-Date	Dec 24, 2019	Current Ratio	4.82	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	- -
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.12	Prev Close	17.52
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	507.43K	Price	18.45
SMA20	3.44%	SMA50	3.44%	SMA200	3.44%	Trades		Volume	53,059	Change	5.30%

Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +5.30%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

Open in Screener

DNTH

Dianthus Therapeutics Inc

Sep 20 • 03:19PM ET

28.88

Dollar change +0.78
Percentage change 2.79	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

DNTH Dianthus Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO IWC AVSC VHT ITOT SBIO

Index	RUT	P/E	-	EPS (ttm)	-5.54	Insider Own	31.61%	Shs Outstand	29.35M	Perf Week	-0.27%
Market Cap	847.70M	Forward P/E	-	EPS next Y	-2.81	Insider Trans	0.00%	Shs Float	20.08M	Perf Month	1.24%
Income	-56.68M	PEG	-	EPS next Q	-0.61	Inst Own	78.54%	Short Float	21.44%	Perf Quarter	13.13%
Sales	4.12M	P/S	205.75	EPS this Y	73.22%	Inst Trans	5.06%	Short Ratio	17.05	Perf Half Y	3.37%
Book/sh	12.20	P/B	2.37	EPS next Y	-24.22%	ROA	-25.33%	Short Interest	4.30M	Perf Year	118.48%
Cash/sh	12.29	P/C	2.35	EPS next 5Y	-	ROE	-26.19%	52W Range	6.58 - 33.77	Perf YTD	177.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.95%	ROI	-15.82%	52W High	-14.47%	Beta	1.85
Dividend TTM	-	Quick Ratio	36.46	Sales past 5Y	-11.19%	Gross Margin	91.74%	52W Low	338.95%	ATR (14)	1.73
Dividend Ex-Date	-	Current Ratio	36.46	EPS Y/Y TTM	69.59%	Oper. Margin	-1669.82%	RSI (14)	55.22	Volatility	6.91% 5.94%
Employees	53	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1376.42%	Recom	1.20	Target Price	50.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	40.63%	Payout	-	Rel Volume	1.17	Prev Close	28.10
Sales Surprise	405.01%	EPS Surprise	6.46%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	252.54K	Price	28.88
SMA20	3.72%	SMA50	3.15%	SMA200	25.44%	Trades		Volume	265,321	Change	2.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21
Jan-07-21	Initiated	Mizuho	Buy	$16
Jun-08-20	Upgrade	Goldman	Neutral → Buy	$15
Mar-25-19	Downgrade	Goldman	Buy → Neutral	$17 → $16
Mar-15-19	Initiated	Raymond James	Outperform

Show Previous Ratings

Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
04:30PM	Loading…
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
01:24PM	Loading…
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)
Apr-14-22 04:41PM	Stem cell startup cuts staff by 14% (American City Business Journals) -7.05% -14.29%
12:15PM	Magenta Therapeutics Trims R&D, Cuts Workforce (Benzinga)
08:00AM	Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway (Business Wire)
Mar-08-22 08:00AM	Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights (Business Wire) +7.06%
Mar-03-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference (Business Wire)
Feb-07-22 09:35AM	What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares? (Simply Wall St.)
Jan-18-22 07:00AM	Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform (GlobeNewswire)
Jan-10-22 08:00AM	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 (Business Wire)
Jan-05-22 08:00AM	Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference (Business Wire) -6.50%
Dec-14-21 09:00AM	Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-10-21 06:20AM	Big Pharma Is Going Holiday Shopping. Who's Next? (Motley Fool)
Nov-08-21 09:24AM	Companies Like Magenta Therapeutics (NASDAQ:MGTA) Are In A Position To Invest In Growth (Simply Wall St.) -6.36%
Nov-04-21 09:10AM	Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights (Business Wire)
09:09AM	Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-04-21 08:00AM	Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer (Business Wire)
Sep-21-21 08:00AM	Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference (Business Wire)
Sep-15-21 08:00AM	Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial (Business Wire) +8.16%
Aug-09-21 06:20AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
Aug-05-21 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (Business Wire)
Aug-03-21 05:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire) -10.97%
08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August (Business Wire)
Aug-01-21 11:50AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (Newsfile)
Jul-30-21 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (ACCESSWIRE)
11:14AM	Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)? (Insider Monkey)
Jul-28-21 07:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire)
Jul-26-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (GlobeNewswire)
Jul-23-21 11:00AM	MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Magenta Therapeutics, Inc. Investigation (ACCESSWIRE)
10:14AM	2 Strong Buy Stocks Under $10 With Strong Growth Prospects (TipRanks)
Jul-21-21 10:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire) -9.33% -6.94%
03:46PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Investigation (ACCESSWIRE)
08:47AM	Magenta Therapeutics Stock Drops As FDA Issues Clinical Hold On Blood Cancer Candidate IND (Benzinga)
08:00AM	Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (Business Wire)
Jul-14-21 10:00AM	After Plunging 21% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
Jul-06-21 08:00AM	Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer (Business Wire)
Jun-17-21 09:43AM	Gene Therapy Companies Undervalued, Positioned for Upside (TipRanks)
Jun-14-21 08:00AM	Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer (Business Wire)
Jun-04-21 09:00AM	Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Jun-03-21 08:00AM	Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference (Business Wire)
May-14-21 08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May (Business Wire)
May-12-21 10:00AM	Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117 (Business Wire) +9.48%
10:00AM	Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors (Business Wire)
May-06-21 08:00AM	Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights (Business Wire) -7.05%
May-03-21 06:41AM	We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate (Simply Wall St.)
Apr-19-21 08:00AM	Magenta Therapeutics Appoints David Nichols as Chief Technical Officer (Business Wire)
Mar-25-21 08:00AM	Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference (Business Wire)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Sep 29 '23	Buy	13.63	24,670	336,252	1,928,503	Oct 03 04:00 PM
Fairmount Funds Management LLC	Director	Sep 26 '23	Buy	13.15	30,000	394,500	1,903,833	Sep 28 05:09 PM
Randhawa Simrat	Chief Medical Officer	Sep 22 '23	Buy	13.20	2,000	26,400	4,000	Sep 25 04:15 PM
Randhawa Simrat	Chief Medical Officer	Sep 21 '23	Buy	13.20	2,000	26,400	2,000	Sep 25 04:15 PM

Open in Screener

APGE

Apogee Therapeutics Inc.

Sep 20 • 03:19PM ET

58.10

Dollar change +5.15
Percentage change 9.73	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

APGE Apogee Therapeutics Inc. daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA LABU VHT

Index	RUT	P/E	-	EPS (ttm)	-2.28	Insider Own	37.94%	Shs Outstand	37.17M	Perf Week	13.08%
Market Cap	3.40B	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-0.54%	Shs Float	36.29M	Perf Month	20.17%
Income	-118.48M	PEG	-	EPS next Q	-0.78	Inst Own	76.98%	Short Float	22.81%	Perf Quarter	52.90%
Sales	0.00M	P/S	-	EPS this Y	16.88%	Inst Trans	-	Short Ratio	18.81	Perf Half Y	-12.68%
Book/sh	13.65	P/B	4.26	EPS next Y	-35.84%	ROA	-25.44%	Short Interest	8.28M	Perf Year	178.80%
Cash/sh	11.56	P/C	5.03	EPS next 5Y	-	ROE	-26.73%	52W Range	14.19 - 72.29	Perf YTD	107.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-15.27%	52W High	-19.63%	Beta	2.79
Dividend TTM	-	Quick Ratio	27.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	309.46%	ATR (14)	2.92
Dividend Ex-Date	-	Current Ratio	27.70	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	71.31	Volatility	5.80% 5.20%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	85.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-60.56%	Payout	-	Rel Volume	1.50	Prev Close	52.95
Sales Surprise	-	EPS Surprise	-3.58%	Sales Q/Q	-	Earnings	Aug 12 BMO	Avg Volume	440.08K	Price	58.10
SMA20	17.66%	SMA50	21.87%	SMA200	31.47%	Trades		Volume	592,953	Change	9.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
06:30AM	Loading…
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Loading…
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	Loading…
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)
Aug-10-23 02:29PM	FMR LLC Acquires New Stake in Apogee Therapeutics Inc (GuruFocus.com)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 07:30AM	Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-02-23 07:30AM	Apogee Therapeutics to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-18-23 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Chief Medical Officer	Sep 04 '24	Sale	47.56	6,665	316,969	280,793	Sep 06 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sep 04 '24	Sale	47.62	40,000	1,904,841	1,394,487	Sep 06 08:02 PM
HENDERSON MICHAEL THOMAS	Officer	Sep 04 '24	Proposed Sale	47.62	40,000	1,904,848		Sep 04 01:35 PM
Henderson Jane	Chief Financial Officer	Aug 23 '24	Sale	48.26	6,000	289,560	200,871	Aug 23 08:05 PM
JANE V HENDERSON	Officer	Aug 23 '24	Proposed Sale	48.26	6,000	289,570		Aug 23 04:09 PM
Dambkowski Carl	Chief Medical Officer	Aug 07 '24	Sale	40.67	7,335	298,336	287,458	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Aug 07 '24	Sale	40.62	40,000	1,624,764	1,434,487	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Officer	Aug 07 '24	Proposed Sale	40.62	40,000	1,624,784		Aug 07 01:18 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 05 '24	Sale	37.26	15,000	558,900	1,474,487	Jul 05 08:01 PM
Dambkowski Carl	Chief Medical Officer	Jul 03 '24	Sale	37.60	5,995	225,418	294,793	Jul 05 08:01 PM

Open in Screener

COGT

Cogent Biosciences Inc

Sep 20 • 03:19PM ET

10.93

Dollar change +0.03
Percentage change 0.28	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

COGT Cogent Biosciences Inc daily Stock Chart

Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	21.37%	Shs Outstand	86.12M	Perf Week	2.82%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-2.30	Insider Trans	0.00%	Shs Float	86.06M	Perf Month	6.74%
Income	-227.04M	PEG	-	EPS next Q	-0.57	Inst Own	90.36%	Short Float	11.92%	Perf Quarter	24.35%
Sales	0.00M	P/S	-	EPS this Y	4.15%	Inst Trans	3.51%	Short Ratio	10.71	Perf Half Y	63.87%
Book/sh	2.37	P/B	4.61	EPS next Y	0.98%	ROA	-55.22%	Short Interest	10.25M	Perf Year	9.63%
Cash/sh	3.32	P/C	3.29	EPS next 5Y	-	ROE	-62.92%	52W Range	3.67 - 12.14	Perf YTD	85.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.33%	ROI	-58.23%	52W High	-9.97%	Beta	1.72
Dividend TTM	-	Quick Ratio	9.25	Sales past 5Y	-6.78%	Gross Margin	-	52W Low	197.82%	ATR (14)	0.61
Dividend Ex-Date	-	Current Ratio	9.25	EPS Y/Y TTM	-12.63%	Oper. Margin	0.00%	RSI (14)	57.94	Volatility	5.20% 6.03%
Employees	164	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.36	Target Price	16.45
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-0.75%	Payout	-	Rel Volume	0.53	Prev Close	10.90
Sales Surprise	-	EPS Surprise	-5.92%	Sales Q/Q	-	Earnings	Aug 06 BMO	Avg Volume	957.15K	Price	10.93
SMA20	3.26%	SMA50	12.31%	SMA200	44.11%	Trades		Volume	453,757	Change	0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral	$14 → $8
Feb-08-24	Initiated	Citigroup	Buy	$11
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral	$5
Dec-08-23	Initiated	JP Morgan	Overweight	$18
Apr-28-23	Initiated	Robert W. Baird	Outperform	$20
Mar-27-23	Resumed	H.C. Wainwright	Buy	$28
Dec-14-22	Initiated	Needham	Buy	$24
Jun-28-22	Initiated	Guggenheim	Buy	$15
Oct-11-21	Initiated	H.C. Wainwright	Buy	$25
Jun-09-21	Resumed	Jefferies	Buy	$20
Dec-23-20	Initiated	Piper Sandler	Overweight	$22
Oct-14-20	Initiated	Ladenburg Thalmann	Buy	$4

Show Previous Ratings

Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
07:30AM	Loading…
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Cogent Biosciences Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 09:00AM	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor (GlobeNewswire) +7.21%
Mar-13-24 07:06AM	5 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	COGT Reports Full Year 2023 Financial Results and Business Highlights (GuruFocus.com)
Feb-26-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 02:30PM	Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (GlobeNewswire)
07:00AM	Loading…
Feb-14-24 07:00AM	Cogent Biosciences Announces Oversubscribed $225 Million Private Placement (GlobeNewswire) +59.34%
Feb-05-24 09:00AM	Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting (GlobeNewswire) +18.75%
Jan-09-24 08:00AM	Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire) -7.73%
Jan-02-24 08:00AM	Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.12%
Dec-11-23 07:55AM	Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) -53.01%
Dec-09-23 01:30PM	Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Dec-07-23 09:00AM	Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K inhibitor programs at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 08:00AM	Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-29-23 08:00AM	Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium (GlobeNewswire) +5.67%
Nov-02-23 09:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-14-23 12:30PM	Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-13-23 08:51AM	After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain (Simply Wall St.)
Aug-08-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire) +7.62%
Jul-10-23 07:35PM	Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023 (TipRanks)
Jun-09-23 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
09:00AM	Loading…
Jun-07-23 09:00AM	Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference (GlobeNewswire) -10.21%
Jun-06-23 08:25PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire)
04:05PM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-03-23 02:15PM	Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-23-23 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-09-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-17-23 09:00AM	Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis (GlobeNewswire) +6.62%
Apr-12-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.74%
Mar-14-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.54%
Feb-01-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-11-23 11:03AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics (GlobeNewswire)
Jan-05-23 08:00AM	Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 05:30PM	Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-05-22 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (GlobeNewswire)
Nov-28-22 04:15PM	Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development (GlobeNewswire) +6.14%
Nov-14-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.63%
Nov-03-22 09:05AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-26-22 07:00AM	Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting (GlobeNewswire)
Aug-14-22 12:21PM	2 Monster Growth Stocks That Could Reach New Highs (TipRanks)
Aug-09-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 11:22AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.) +12.58%
Jun-20-22 11:09AM	Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions? (Simply Wall St.)
Jun-16-22 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.47% +17.82%
Jun-13-22 09:48PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants (GlobeNewswire) +11.05%
06:00AM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-10-22 07:00AM	Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) +58.67%
Jun-06-22 10:15AM	Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET (GlobeNewswire)
Jun-02-22 08:00AM	Cogent Biosciences Announces Annual Meeting of Stockholders (GlobeNewswire)
May-12-22 10:00AM	Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.11%
May-10-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire) -8.29%
May-06-22 08:00AM	Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium (GlobeNewswire)
Apr-11-22 07:00AM	Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event (GlobeNewswire)
Mar-29-22 07:00AM	Cogent Biosciences to Host Virtual R&D Investor Event (GlobeNewswire) +5.79%
Mar-15-22 07:00AM	Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-08-22 05:10PM	Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022 (GlobeNewswire)
Feb-01-22 05:29AM	Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 07:00AM	Cogent Biosciences Provides 2022 Corporate Guidance (PR Newswire)
Nov-22-21 07:00AM	Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (PR Newswire) -6.12%
Nov-10-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-02-21 07:00AM	Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021 (PR Newswire)
Oct-29-21 09:46AM	Hedge Funds Are Dumping Cogent Biosciences, Inc. (COGT) (Insider Monkey)
Oct-12-21 07:59PM	2 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks) +10.94%
Oct-07-21 09:00AM	Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration (PR Newswire)
Oct-01-21 07:00AM	Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference (PR Newswire)
Aug-16-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results (PR Newswire)
Jul-27-21 07:00AM	Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021 (PR Newswire)
Jul-13-21 11:11AM	Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy? (Insider Monkey)
Jun-29-21 07:00AM	Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021 (PR Newswire)
Jun-15-21 11:37AM	2 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside (TipRanks)
May-26-21 07:00AM	Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021 (PR Newswire) +5.65%
May-12-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results (PR Newswire)
May-03-21 07:00AM	Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer (PR Newswire)
Apr-06-21 07:00AM	Cogent Biosciences Announces Creation of Cogent Research Team (PR Newswire)
Mar-17-21 02:27AM	Do Institutions Own Cogent Biosciences, Inc. (NASDAQ:COGT) Shares? (Simply Wall St.)
Mar-16-21 07:00AM	Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results (PR Newswire) +6.72%
Feb-22-21 07:00AM	Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors (PR Newswire) -5.60%
Feb-18-21 07:00AM	Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 (PR Newswire)
Feb-11-21 07:00AM	Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021 (PR Newswire)
Dec-04-20 05:16PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares (PR Newswire)
Dec-01-20 11:08PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (PR Newswire) +6.73% +16.62%
Nov-30-20 04:01PM	Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock (PR Newswire)
07:00AM	Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer (PR Newswire)
Nov-20-20 07:00AM	Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference (PR Newswire)
Nov-18-20 09:00AM	Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020 (PR Newswire)
Nov-12-20 04:30PM	Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference (PR Newswire)
Nov-09-20 07:00AM	Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates (PR Newswire)
Nov-05-20 07:00AM	Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference (PR Newswire) -5.32%
Oct-26-20 07:00AM	Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer (PR Newswire)

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc.

DNTH

Dianthus Therapeutics Inc

APGE

Apogee Therapeutics Inc.

COGT

Cogent Biosciences Inc

Upgrade your FINVIZ experience